Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland



The aim of this study was an analysis of the population effects of a seven-valent pneumococcal conjugate vaccine (PCV7) on pneumonia incidence rates in the 5-year follow-up period after the introduction in 2006 of a universal PCV7 vaccination programme in the city of Kielce, Poland. Vaccinations were carried out according to a 2 + 1 schedule. The vaccination compliance rate amounted to approximately 99 %. The age groups 0–2, 30–49, 50–65 and 65+ years were analysed. The Cochran–Armitage test was used to investigate the significance of observed trends in pneumonia morbidity. The significance of deviations from a linear trend was also tested. The importance of the trend was confirmed by the Mantel test. Between 2005 and 2010, the greatest decline, 82.9 % (2005, 25.31/1,000; 2010, 4.34/1,000), in pneumonia morbidity was observed for children <2 years of age. In the 65+ years age group, this amounted to 43.5 %. Lesser declines, but still of statistical significance, were observed for the other age groups: 16.5 % in the 30–49 years group and 40.4 % in the 50–64 years group. All reductions are statistically significant and confirmed by the Mantel test. Five years after the introduction of a universal PCV7 vaccination programme in Kielce, Poland, its effectiveness in pneumonia prevention has been demonstrated in both the <2 years of age group and indirectly for other groups.


  1. 1.
    Williams BG, Gouws E, Boschi-Pinto C et al (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2:25–32PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization (WHO) Global Immunization Vision and Strategy, April 2005. Available online at:
  3. 3.
    Foy HM, Cooney MK, Allan I et al (1979) Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 241:253–258PubMedCrossRefGoogle Scholar
  4. 4.
    Murphy TF, Henderson FW, Clyde WA Jr et al (1981) Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 113:12–21PubMedGoogle Scholar
  5. 5.
    McConnochie KM, Hall CB, Barker WH (1988) Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice. Am J Public Health 78:34–39PubMedCrossRefGoogle Scholar
  6. 6.
    Michelow IC, Olsen K, Lozano J et al (2004) Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113:701–707PubMedCrossRefGoogle Scholar
  7. 7.
    Korppi M, Heiskanen-Kosma T, Jalonen E et al (1993) Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 152:24–30PubMedCrossRefGoogle Scholar
  8. 8.
    Drummond P, Clark J, Wheeler J et al (2000) Community acquired pneumonia—a prospective UK study. Arch Dis Child 83:408–412PubMedCrossRefGoogle Scholar
  9. 9.
    Marston BJ, Plouffe JF, File TM Jr et al (1997) Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 157(15):1709–1718PubMedCrossRefGoogle Scholar
  10. 10.
    Black S, Shinefield H, Fireman B et al (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19:187–195PubMedCrossRefGoogle Scholar
  11. 11.
    Black SB, Shinefield HR, Ling S et al (2002) Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21:810–815PubMedCrossRefGoogle Scholar
  12. 12.
    Grijalva CG, Nuorti JP, Arbogast PG et al (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179–1186PubMedCrossRefGoogle Scholar
  13. 13.
    Zhou F, Kyaw MH, Shefer A et al (2007) Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 161:1162–1168PubMedCrossRefGoogle Scholar
  14. 14.
    Adam D, Fehnle K (2008) Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Vaccine 26(47):5944–5951PubMedCrossRefGoogle Scholar
  15. 15.
    Durando P, Crovari P, Ansaldi F et al; Collaborative Group for Pneumococcal Vaccination in Liguria (2009) Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 27(25–26):3459–3462PubMedCrossRefGoogle Scholar
  16. 16.
    Pírez MC, Algorta G, Cedrés A et al (2011) Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 30(8):669–674PubMedCrossRefGoogle Scholar
  17. 17.
    Patrzałek M, Albrecht P, Sobczynski M (2010) Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 29(7):787–792PubMedCrossRefGoogle Scholar
  18. 18.
    Centers for Disease Control and Prevention (CDC) (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. MMWR Morb Mortal Wkly Rep 54(36):893–897Google Scholar
  19. 19.
    Jardine A, Menzies RI, McIntyre PB (2010) Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 29(7):607–612PubMedCrossRefGoogle Scholar
  20. 20.
    Simonsen L, Taylor RJ, Young-Xu Y et al (2010) Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2(1):e00309–e00310. doi:10.1128/mBio.00309-10 Google Scholar
  21. 21.
    Käyhty H, Åhman H, Eriksson K et al (2005) Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J 24:108–114PubMedCrossRefGoogle Scholar
  22. 22.
    Esposito S, Pugni L, Bosis S et al (2005) Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23:1703–1708PubMedCrossRefGoogle Scholar
  23. 23.
    Epidemiologic Perspectives & Innovations 2004, 1:6 ( WINPEPI programs and manuals are available free at:
  24. 24.
    McIntosh K (2002) Community-acquired pneumonia in children. N Engl J Med 346:429–437PubMedCrossRefGoogle Scholar
  25. 25.
    Advisory Committee on Immunization Practices (2000) Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49(RR-9):1–35Google Scholar
  26. 26.
    Grzesiowski P, Skoczyńska A, Albrecht P et al; Polish Pediatric IPD Group (2008) Invasive pneumococcal disease in children up to 5 years of age in Poland. Eur J Clin Microbiol Infect Dis 27:883–885PubMedCrossRefGoogle Scholar
  27. 27.
    Skoczyńska A, Sadowy E, Bojarska K et al (2011) The current status of invasive pneumococcal disease in Poland. Vaccine 29:2199–2205PubMedCrossRefGoogle Scholar
  28. 28.
    Flasche S, Van Hoek AJ, Sheasby E et al (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8(4):e1001017. doi:10.1371/journal.pmed.1001017 PubMedCrossRefGoogle Scholar
  29. 29.
    Cutts FT, Zaman SM, Enwere G et al; Gambian Pneumococcal Vaccine Trial Group (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365:1139–1146PubMedCrossRefGoogle Scholar
  30. 30.
    Klugman KP, Madhi SA, Huebner RE et al; Vaccine Trialists Group (2003) A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349:1341–1348PubMedCrossRefGoogle Scholar
  31. 31.
    O’Brien KL, Dagan R (2003) The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 21:1815–1825PubMedCrossRefGoogle Scholar
  32. 32.
    Levine OS, O’Brien KL, Knoll M et al (2006) Pneumococcal vaccination in developing countries. Lancet 367:1880–1882PubMedCrossRefGoogle Scholar
  33. 33.
    van Gils EJ, Veenhoven RH, Hak E et al (2009) Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302:159–167PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.NZOZ “Promed”KielcePoland
  2. 2.National Institute of Public Health, National Institute of HygieneWarsawPoland
  3. 3.Department of Pediatric Gastroenterology and NutritionMedical University of WarsawWarsawPoland

Personalised recommendations